Top Page
Imugene
(Sydney:IMU)
Imugene (IMU) vs. iShares MSCI Australia ETF (EWA)
Imugene Business Overview & Revenue Model
Imugene Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.40M | 4.40M | 4.97M | 11.78M | 12.97M | 7.23M |
| Gross Profit | 4.40M | 4.40M | 4.97M | 9.57M | 10.56M | 5.27M |
| EBITDA | -67.42M | -67.42M | -147.98M | -47.42M | -48.06M | -23.72M |
| Net Income | -69.02M | -69.02M | -149.68M | -37.91M | -37.87M | -18.45M |
Balance Sheet | ||||||
| Total Assets | 83.59M | 83.59M | 151.40M | 197.06M | 147.61M | 71.81M |
| Cash, Cash Equivalents and Short-Term Investments | 21.94M | 21.94M | 94.54M | 153.15M | 99.89M | 29.49M |
| Total Debt | 10.65M | 10.65M | 2.19M | 553.47K | 673.43K | 271.03K |
| Total Liabilities | 38.56M | 38.56M | 33.14M | 7.44M | 8.90M | 6.79M |
| Stockholders Equity | 45.03M | 45.03M | 118.25M | 189.63M | 138.70M | 65.02M |
Cash Flow | ||||||
| Free Cash Flow | -83.12M | -90.03M | -108.80M | -29.78M | -30.93M | -18.58M |
| Operating Cash Flow | -75.57M | -75.57M | -101.73M | -29.78M | -30.67M | -13.13M |
| Investing Cash Flow | -12.70M | -12.70M | -7.25M | 9.63K | -414.16K | -5.48M |
| Financing Cash Flow | 17.37M | 17.37M | 49.43M | 82.98M | 101.35M | 17.99M |
Imugene Technical Analysis
Imugene Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | AU$47.32M | -4.95 | -49.72% | ― | ― | 10.78% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | AU$117.12M | -4.72 | ― | ― | ― | 0.66% | |
41 Neutral | AU$97.88M | ― | -42.68% | ― | ― | 63.46% | |
41 Neutral | $96.17M | ― | -83.09% | ― | ― | 55.94% | |
40 Underperform | $149.98M | ― | -81.03% | ― | -20.79% | 73.98% | |
40 Underperform | AU$106.68M | -13.09 | -47.98% | ― | 700.00% | 26.88% |
Imugene Corporate Events
Imugene Limited announced an upcoming webinar to discuss early efficacy results from their azer-cel Phase 1b trial for CAR T naïve lymphomas and their presentation at the 67th American Society of Hematology Annual Meeting. This initiative reflects Imugene’s commitment to advancing cancer treatment and engaging stakeholders, potentially strengthening its position in the immuno-oncology market.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene Limited announced that its abstract on azer-cel, an allogeneic CD19 CAR T therapy, has been selected for oral presentation at the 67th American Society of Hematology Annual Meeting in Florida. This selection highlights the clinical interest in allogeneic CAR T approaches and provides an opportunity for Imugene to present new insights from their ongoing study on relapsed or refractory large B-cell lymphoma, potentially impacting the company’s industry positioning and stakeholder engagement.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene Limited has issued 19,491,635 fully paid ordinary shares to Precision Biosciences, Inc. as part of a milestone achievement under their License Agreement. This issuance reflects Imugene’s progress in its strategic collaboration with Precision Biosciences, potentially enhancing its market position in the immuno-oncology sector. The move signifies Imugene’s commitment to advancing its clinical and commercial milestones, aligning with its vision to become a leader in the rapidly growing global cancer treatment market.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene Limited has announced the issuance of 19,491,635 fully paid ordinary shares to Precision Biosciences, Inc., marking the achievement of a significant milestone under their License Agreement dated August 16, 2023. This development is expected to enhance Imugene’s operational capabilities and strengthen its position in the biotechnology sector by advancing its collaborative efforts with Precision Biosciences.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene Limited has announced a significant milestone in its Phase 1b clinical trial of azer-cel, an allogeneic CD19 CAR T-cell therapy, which has achieved an 81% overall response rate in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The trial’s success, including rapid and durable responses, positions Imugene favorably in the immuno-oncology sector, with potential implications for expanding treatment options for rare lymphomas. Additionally, the company has raised approximately $25 million through an institutional placement and share purchase plan, and received a $5.9 million R&D tax refund, bolstering its financial position to support ongoing research and development efforts.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene Limited has announced promising early efficacy results from its Phase 1b trial of azer-cel, an allogeneic CD19 CAR T therapy, in CAR T-naïve patients with various B-cell lymphomas. The trial showed an 83% overall response rate and a 50% complete response rate among the six evaluable patients, with enrolment progressing faster than previous cohorts. This progress highlights the substantial clinical demand and potential for expedited clinical paths, particularly in areas of unmet need.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene Limited announced that its PD1-Vaxx colorectal cancer trial will be featured at the ESMO Congress 2025, highlighting its growing international clinical presence. The Neo-POLEM Phase II trial aims to assess the efficacy of PD1-Vaxx, a novel B-cell vaccine, in treating early-stage MSI-high colorectal cancer, potentially offering an alternative to existing monoclonal antibody therapies. The trial, which began recruitment in May 2025, is a collaborative effort involving multiple sites in the UK and Australia, and seeks to improve treatment outcomes for colorectal cancer patients.
The most recent analyst rating on (AU:IMU) stock is a Buy with a A$0.82 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene Limited has announced the quotation of 2,206 ordinary fully paid securities on the Australian Securities Exchange (ASX). This move is part of the company’s strategy to enhance its financial flexibility and support its ongoing projects in cancer immunotherapy. The issuance of these securities reflects Imugene’s commitment to expanding its market presence and advancing its research and development efforts, potentially benefiting stakeholders through increased investment opportunities.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene Limited has announced its 2025 Annual General Meeting, which will address key business matters such as adopting the 2025 Remuneration Report, re-electing directors, and approving equity incentives. The company has made enhancements to its remuneration approach, emphasizing transparency and alignment with performance metrics, and the board intends to forego 50% of equity incentives as a gesture of confidence in challenging capital markets.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene Limited has announced promising results from its Phase 1b clinical trial of azer-cel, an allogeneic off-the-shelf CD19 CAR T therapy for relapsed diffuse large B-cell lymphoma (DLBCL). The trial has achieved an 81% overall response rate, with 7 complete responses and 6 partial responses among patients who have previously failed multiple lines of therapy. This development highlights the potential of azer-cel in addressing high unmet needs in the treatment of aggressive blood cancers and expands its application to other lymphoma types. The trial is actively enrolling patients in the U.S. and Australia, with additional updates expected in the coming months.
The most recent analyst rating on (AU:IMU) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene Limited has announced the issuance of 5,501,568 quoted options, set to expire on March 30, 2026, at an exercise price of $0.43. These options have been allocated to participants of the Share Purchase Plan (SPP), reflecting the company’s strategic efforts to enhance its financial position and support its ongoing projects in the biotechnology sector.
The most recent analyst rating on (AU:IMU) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene Limited has announced the quotation of 7,335,608 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of September 1, 2025. This move is part of a previously announced transaction, which may enhance the company’s financial flexibility and market presence, potentially impacting its operations and stakeholder interests positively.
The most recent analyst rating on (AU:IMU) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene Limited has successfully completed its Share Purchase Plan, raising $2.42 million through the issuance of over 7.3 million shares at $0.33 each. This follows a prior institutional placement that raised $22.5 million. The funds will support Imugene’s ongoing efforts in developing novel cancer therapies, reinforcing its position in the immuno-oncology sector and demonstrating strong investor confidence in its strategic direction.
The most recent analyst rating on (AU:IMU) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene Limited has released a report detailing the top holders of its securities, with HSBC Custody Nominees (Australia) Limited holding the largest share at 15.61%. This report provides insights into the company’s shareholder structure, which could influence investor confidence and market perception.
The most recent analyst rating on (AU:IMU) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene Limited has announced a new application for the quotation of securities on the Australian Securities Exchange (ASX). The company plans to quote 51,177,612 new securities, specifically Quoted Options expiring on March 30, 2026, at an exercise price of $0.43. This move could potentially enhance the company’s financial flexibility and support its ongoing research and development efforts in the immuno-oncology sector.
The most recent analyst rating on (AU:IMU) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene Limited is a clinical-stage immuno-oncology company focused on developing innovative cancer treatments that activate the immune system to target and eliminate tumors. The company is supported by a team of international cancer experts and aims to improve patient outcomes through its unique platform technologies.
Imugene Limited has released its Corporate Governance Statement for the financial year ending June 30, 2025, in compliance with ASX Listing Rule 4.10.3. The statement outlines the company’s adherence to the ASX Corporate Governance Council’s Principles and Recommendations, detailing its governance framework, board responsibilities, and performance evaluations. This document highlights Imugene’s commitment to maintaining high standards of ethics, integrity, and statutory compliance, which are crucial for its strategic direction and operational management. The statement also addresses areas where recommendations were not fully followed, ensuring transparency and accountability to stakeholders.
The most recent analyst rating on (AU:IMU) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene Limited announced the successful outcomes of its Extraordinary General Meeting, where all resolutions were passed. This development underscores the company’s strategic direction and commitment to advancing its immuno-oncology therapies, potentially strengthening its position in the rapidly evolving cancer treatment market.
The most recent analyst rating on (AU:IMU) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene Limited announced an update regarding its Share Purchase Plan, extending the closing date for the proposed issue of securities. This extension aims to provide shareholders with additional time to participate in the offer, potentially impacting the company’s capital raising efforts and shareholder engagement. The announcement reflects Imugene’s strategic approach to managing its financial resources and maintaining investor interest.
The most recent analyst rating on (AU:IMU) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
Imugene Limited has announced an extension to the closing date of its $15 million share purchase plan (SPP) to 25 August 2025, allowing shareholders additional time to consider the offer. This decision follows feedback from shareholders and is part of the company’s broader fundraising efforts, which include a recently completed $22.5 million placement. The extension aims to ensure greater shareholder participation and engagement, potentially strengthening Imugene’s financial position and supporting its ongoing immunotherapy development initiatives.
The most recent analyst rating on (AU:IMU) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.